TOP BRD4 INHIBITION BY ABBV-744 IN CANCER RESEARCH STUDIES SECRETS

In Section C, participants will acquire ABBV-744 and oral navitoclax. In Segment D, members will receive ABBV-744 and ruxolitinib. Members will acquire treatment until disorder progression or the members are unable to tolerate the study drugs.and after that endorse H3K27Ac at this region. Chromatin hyperacetylation could improve the accessibility f